Clinical trials: Renal Carcinoma
Renal Cell Carcinoma
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
This is an open-label, non-controlled, non-randomized, phase I dose-finding, of Cabometyx + Avelumab, to establish safety, feasibility, and the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of Cabometyx in…
- Trial name
- NCT03200587
- Testing
- Avelumab, Cabozantinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Metastatic Renal Cancer
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs.
- Trial name
- NCT06959433
- Testing
- Lu-177 PSMA-617
- Volunteers
- 20 people
- Sponsor
- Ankara University
Metastatic Clear Cell Renal Carcinoma
A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This is very difficult to treat and almost all patients will die of their disease within 2 years of the diagnosis.
- Trial name
- ZEBRA (NCT01793636)
- Testing
- AZD2014, Everolimus
- Where
- 9 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Queen Mary University of London
Kidney Cancer
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2).
- Trial name
- RESTRICT (NCT04922307)
- Testing
- Blood Sparing Protocol, Standard Blood Replacement
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanderbilt University Medical Center
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
- Trial name
- BREAKPOINT (NCT03463681)
- Testing
- Cabometyx
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Renal Pelvis Cancer
Radical Radiotherapy Versus Radical Surgery for UTUC
This study is a prospective cohort study, and the proposed plan is to recruit 30 patients with radical radiotherapy for renal pelvic ureteral cancer, according to the actual clinical situation, enrolling the same period of time…
- Trial name
- NCT06652009
- Testing
- Radical nephroureterectomy, Radical radiotherapy
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Carcinoma, Renal Cell
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI)…
- Trial name
- NCT06222593
- Testing
- Bicalutamide in combination with Sunitinib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- State University of New York at Buffalo
Carcinoma, Renal Cell, Prostatic Neoplasms
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable…
- Trial name
- NCT00106301
- Testing
- FK228 (romidepsin)
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Celgene
Breast Cancer, Lung Cancer
Pillars4Life Trial
This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving…
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer
- Trial name
- Pillars4Life (NCT02465892)
- Testing
- Pillars4Life
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- Duke University
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Trial name
- NCT01672775
- Testing
- AGS-16C3F
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Agensys, Inc.
Renal Cell Carcinoma
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma
This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies.
- Trial name
- NCT01441661
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Cancer Foundation, China
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy…
- Trial name
- NCT03729245
- Testing
- bempegaldesleukin, sunitinib, nivolumab
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 623 people
- Sponsor
- Nektar Therapeutics
Renal Cell Carcinoma Stage I
An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus
This single-arm exploratory study included patients with renal clear cell carcinoma who had previously received one type of immunotherapy and failed. The specific regimen was Vorolanib 200mg PO.QD combined with everolimus 5mg QD.
- Trial name
- NCT06730672
- Testing
- Vorolanib combined with Everolimus Formation
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02543645
- Testing
- Combination of Varlilumab and Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Celldex Therapeutics
Kidney Cancer
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer.
- Trial name
- NCT00014183
- Testing
- gefitinib
- Where
- 2 sites in United States
- Sponsor
- University of Maryland, Baltimore
Wilms Tumor
Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital
The goal of this cross sectional observational study is to determine the percentage of Wilms tumors among pediatric cancers at Shefa Al-Orman Children Cancer Hospital from june 2020 to june 2024,to study the outcome of patients…
- Trial name
- NCT06288802
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- South Egypt Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.